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Abstract: Background: Worldwide, Streptococcus pyogenes is the leading cause of bacterial 
pharyngitis. To reduce the use of antibiotics, antimicrobial phytochemical-containing remedies, 
which have long been in use in traditional medicine, may provide new approaches for management 
of streptococcal pharyngitis. The objective of this study was to assess the inhibitory activities of 25 
natural phenolic compounds against three strains of S. pyogenes. Methods: After an initial screening, 
the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of the 
nine most effective phenolic compounds were determined. The effect of four compounds with the 
lowest MIC and MBC on streptococcal growth and biofilm formation was also studied. Results: 1,2-
Naphthoquinone and 5-hydroxy-1,4-naphthoquinone elicited the greatest anti-S. pyogenes activities 
with MICs ranging from 0.39 to 6.25 µg mL−1 and MBCs of 100 µg mL−1. Both naphthoquinones 
inhibited the biofilm formation at concentrations ranging from 12.5 to 50 µg mL−1. Biofilm reduction 
and altered bacterial cell structures were visible in scanning electron microscopy images of 
naphthoquinone-treated cells. Conclusion: In conclusion, 1,2-naphthoquinone and 5-hydroxy-1,4-
naphthoquinone inhibit S. pyogenes and should be further investigated as candidates for the 
management of streptococcal pharyngitis. 
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1. Introduction 
Pharyngitis or bacterial infection of the throat is a common disease, which is often caused by 
Streptococcus pyogenes [1,2]. Worldwide, S. pyogenes are responsible for an estimated 600 million cases 
of throat infections per year [3]. β-Lactams, such as penicillin, are the preferred antibiotics in the 
treatment of S. pyogenes throat infections, with macrolides being used for patients with β-lactam 
hypersensitivity. However, while resistance to β-lactams has so far not emerged in S. pyogenes, 
resistances were found for macrolides and some quinolones (fluoroquinolone) [3,4]. Moreover, S. 
pyogenes forms biofilm, which has been associated with antibiotic treatment failures [5]. Thus, there 
is an urgent need to find new potent antibacterial and anti-biofilm agents which could find use in 
alternative and/or complementary therapy for streptococcal pharyngitis.  
In addition to treatment with prescribed medications, throat lozenges containing chemical 
anesthetics and antiseptics are being used by patients in the relief of the discomfort associated with 
the infection. The antimicrobial quaternary ammonium compound, dequalinium chloride, is 
similarly used in the treatment of common infections of the mouth and throat and incorporated in 
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candy-based lozenge formulations [6]. The antiseptic and local anesthetic hexylresorcinol has also 
been included as an active ingredient in throat lozenges [7].  
Natural products derived from plants have been used in traditional medicine since the ancient 
times and are, now, being widely studied for incorporation into mainstream products. Plant-derived 
compounds of interest are mostly secondary metabolites, which possess antimicrobial properties 
against microbial pathogens and spoilers [8]. Recently, a diverse range of phytochemical antibacterial 
agents has been reported to suppress the growth of S. pyogenes, including polyphenols (i.e., 
flavonoids) and terpenes [9–12]. A recent review describes the mechanisms of inhibition of different 
Streptococcus species, including S. pyogenes, by phytochemicals through the prevention of the bacterial 
adherence of the pharynx, inhibition of glycolytic enzyme and pH drop, reduction of biofilm, and 
alteration of cell surface hydrophobicity [2]. 
The objective of the present study was to identify, among 25 different commercially available 
plant-derived phenolic compounds, the ones with anti-S. pyogenes activities, which could be 
incorporated in dehydrated honey throat lozenges and similar products. 
2. Material and Methods 
2.1. Bacterial Strains and Growth Conditions 
The experiments used the following human S. pyogenes strains: S. pyogenes ATCC ® 19615 ™, S. 
pyogenes ATCC ® 49399 ™ and a clinical isolate obtained from a patient with pharyngitis 
(Bacteriology, Queen Elizabeth II Hospital, Halifax, NS, Canada). The strains were routinely cultured 
in Brain Heart Infusion (BHI) (Oxoid, Thermo Fisher Scientific, Waltham, MA, USA) media at 37 °C 
under aerobic conditions.  
2.2. Compounds 
Twenty-five phenolic compounds belonging to 12 different classes: three simple phenols 
(eugenol, thymol, and pyrocatechol), three isoflavones (daidzin, daidzein, and genistein), one 
chalcone (phloretin), one chalcone glycoside (phlorizin), two flavan-3-ols (epicatechin and 
epigallocatechin gallate, EGCG), two flavanones (naringenin and hesperidin), two flavones (flavone 
and naringin), two flavonols (myricetin and quercetin hydrate), one flavonol glucoside (quercetin-3-O-
glucoside), one hydroxybenzoates (gallic acid), three hydroxycinnamates (tran-ferulic acid, 
cinnamaldehyde, and warfarin), two naphthoquinones (1.2-naphthoquinone and 5-hydro-1,4-
naphthoquinone), one stilbene (resveratrol), one tannin (tannic acid), and two chemical compounds 
(used as positive controls), one quaternary ammonium compound (dequalinium chloride), and one 
substituted phenol (4-hexylresorcinol) were evaluated for their antibacterial properties. The 
compounds were purchased from Sigma-Aldrich Company (Saint-Louis, MO, USA). Before each 
experiment, the stock solutions were freshly made to a concentration of 10 mg mL−1 in 100% DMSO. 
2.3. Preliminary Screening Using the Micro-Dilution Broth Antibacterial Assay 
The inhibitory effect of the phenolic compounds (100 µg mL−1) was initially assessed on S. 
pyogenes ATCC 19615 and ATCC 49399, using the broth micro-dilution assay as described by Clinical 
and Laboratory Standards Institute [13]. Briefly, in a 96-well micro-plate, 2 µL of the 100 mg mL−1 
stock solution was added to 98 µL of BHI broth in order to reach a final test compound concentration 
of 100 µg ml-1. Finally, for each strain, 100 µL of standardized inoculum was added, resulting in an 
initial bacterial concentration of 5 log10 (CFU mL−1). Bacterial inocula in BHI broth (2 µL water) and 
BHI broth +1% DMSO were also run as a control. The growth of the bacteria was assessed after 
incubation for 24 h at 37 °C by reading the A600 nm using a plate reader (Epoch TM, Biotek, Winooski, 
VT, USA). Each test was done in triplicate. In order to determine the most active compounds, a 
decrease in the A600 nm of 0.1 or more in the presence of the tested compounds in comparison to the 
control (bacteria inocula in BHI +1% DMSO) was considered to be indicative of an inhibition of the 
growth. 
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2.4. Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) 
MIC broth micro-dilution assay was performed as described in the previous section, except 2-
fold dilutions were used to yield final test compound concentrations ranging from 0.19 to 100 µg 
mL−1, on the three S. pyogenes strains. The MIC was determined as the first concentration where the 
decrease of A600 nm was significant (p < 0.05) in comparison with the control. To determine MBC, 30 
µL from each well, where no growth was detected—i.e., compound concentration ≥ MIC—was 
spread on BHI agar plates and incubated for 24–48 h at 37 °C. The lowest compound concentration 
resulting in no growth on the agar plate represented the MBC. Each sample was tested in triplicate 
and each experiment was repeated three times. 
2.5. Time-Kill Assay  
The effect of concentrations ranging from 1 to 16 times MIC of the four most active compounds 
on the growth of S. pyogenes ATCC 19615 was quantified after 0, 2, 4, 6, 8, 10, and 24 h at 37 °C. At 
each time point, an aliquot (100 µL) was pipetted, serially diluted, and plated on BHI agar followed 
by enumeration and calculation of the mean log10 CFU mL−1 of the duplicate samples. Each time-kill 
experiment was repeated in three biologically independent assays (n = 6). 
2.6. Inhibition of Biofilm Formation 
The ability of S. pyogenes to form biofilm in the presence of 1,2-naphthoquinone, 5-hydroxy-1,-
naphthoquinone, dequalinium chloride, or 4-hexylresorcinol (0.19–100 µg mL−1) was assessed by 
measuring the metabolic activity of sessile biofilm cells using a 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) dye assay. After an exposure period of three days at 37 °C, the 
planktonic bacterial cells were eliminated by carefully removing the BHI medium from the wells. 
Adapted MTT assay was performed as described in Vybrant® MTT Cell Proliferation Assay Kit 
Protocol (Thermo Fisher Scientific, Waltham, MA, USA). After incubation for 10 min at 37 °C, the A540 
nm was measured and used to calculate the minimum biofilm inhibitory concentration (MBIC), defined 
as the first concentration where the decrease in A540 nm was significant (p < 0.05) in comparison with the 
control. 
2.7. Scanning Electron Microscopy (SEM) 
S. pyogenes ATCC 19615 biofilms formed (72 h at 37 °C) in the presence of MBIC concentrations 
of 1,2 naphthoquinone, 5-hydroxy 1,4 naphthoquinone, dequalinium chloride, 4-hexylresorcinol 
were prepared in microplates. The S. pyogenes biofilms were also grown in BHI broth (water) and BHI 
broth +1% DMSO as controls. After incubation, a sample fixation method for SEM [14] adapted for 
microplate was performed. After discarding the last solution, the plate was air dried for 2 h in a fume-
hood. The bottom of the wells (location of the biofilms) were then removed with a heated blade and 
mounted on aluminum mounts using the carbon adhesive and finally sputter-coated with gold and 
examined using a Hitachi S-4700 SEM (Tokyo, Japan). 
2.8. Statistical Analysis 
During the determination of the MIC and MBIC, statistically significant differences (Student t-
test (paired, two tailed), p < 0.05) between test compound concentrations and controls were 
determined using the Student t-test on the A600 nm or A540 nm data, respectively. 
3. Results 
The results of the screening test against two S. pyogenes strains, ATCC 19615 and ATCC 49399 
showed that nine compounds exhibited antibacterial activity against at least one strain at the 
concentration of 100 µg mL−1. Six of them, phlorizin, naringenin, myrcetin 1,2-naphthoquinone, 5-
hydroxy-1,4-naphthoquinone, and resveratrol inhibited both strains like the two positive controls. 
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Flavone and thymol affected the growth of strain ATCC 19615 while cinnamaldehyde inhibited only 
ATCC 49399.  
The MIC of those nine phytochemicals (Table 1) varied from 0.39 µg mL−1 to >100 µg mL−1 and 
the MBC from 100 µg mL−1 to >100 µg mL−1 with some sensitivity/resistance variations among strains. 
1,2-Naphthoquinone and 5-hydroxy-1,4-naphthoquinone exhibited the best inhibitory effect with 
similar MIC values relative to the positive controls and were selected for further analysis of their 
effect on bacterial growth and biofilm formation. 
The four compounds that higher concentrations increased the lag phase and the bacterial log10-
reduction (Figure 1). The presence of low concentrations (<12.5 µg mL−1) of 1,2-naphthoquinone 
delayed growth during the first 10 h but after 24 h the bacterial concentration reached around 8 log10 
CFU mL−1 (Figure 1A). A concentration of 25 µg mL−1 displayed a bacteriostatic effect for the first 10 
h, after which growth resumed to reach 5 log10 CFU mL−1 after 24 h. At 50 µg mL−1, the growth was 
inhibited and a bacterial log10-reduction of more than 3.5 log10 CFU mL−1 observed after 24 h. 
 
Figure 1. The effect of several concentrations of the four compounds on the growth of S. pyogenes 
ATCC 19615 at 37 °C: (A) 1,2-naphthoquinone (MIC: 3.125 µg mL−1); (B) 5-hydroxy-1,4-
naphthoquinone (MIC: 1.56 µg mL−1); (C) dequalinium chloride (MIC: 0.39 µg mL−1); and (D) 4-
hexylresorcinol (MIC: 1.56 µg mL−1). Arrows indicate that plate count values were below the detection 
threshold of 1.22 log10 CFU mL−1. 
Administration of 1.56 µg mL−1 5-hydroxy-1,4-naphthoquinone caused populations to remain 
under 6 log10 CFU mL−1 for 10 h; however, after 24 h more than 7 log10 CFU mL−1 was reached (Figure 
1B). A bacteriostatic effect was similarly observed with 3.125 µg mL−1 5-hydroxy-1,4-naphthoquinone 
where bacterial counts were under 6 log10 CFU mL−1 after 24 h. Using concentrations of 6.25 and 12.5 
µg mL−1, numbers stayed around 4–5 log10 CFU mL−1 for 10 h and then dropped about 2 log10 CFU 
mL−1. With 25 µg mL−1, the bacterial concentrations underwent a 2 log10-reduction after 10 h and 
reached the limit of detection (>1.22 log10 CFU mL−1) after 24 h. 
For the dequalinium chloride (Figure 1C), the same trend of inhibition was observed where the 
lowest test concentrations of 0.39 µg mL−1 permitted growth and a twice-higher concentration of 0.78 
µg mL−1 displayed a bacteriostatic effect. After 24 h, the concentrations of 1.56 and 3.125 µg mL−1 
induced more than 2.5 log10 CFU mL−1 and 6.25 µg mL−1 caused a >4 log10-reduction (below the 
detection limit).  
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The concentrations of 4-hexylresorcinol ranging from 1.56 to 6.25 µg mL−1 caused a growth delay 
and a small log10-reduction (under 1 log10 CFU mL−1) after 24 h. However, the concentration of 25 µg 
mL−1 induced a log10-reduction of more than 3 log10 CFU mL−1 after 24 h (Figure 1D).  
The two naphthoquinones as well as the substituted phenol, 4-hexylresorcinol, inhibited biofilm 
formation with MBICs of between 25–50 µg mL−1 for 1,2-naphthoquinone, 12.5–50 µg mL−1 for  
5-hydroxy-1,4-naphthoquinone, and from 12.5 to 25 µg mL−1 for 4-hexylresorcinol (Table 1). 
Dequalinium chloride displayed the lowest MBIC ranging from 0.39–0.78 µg mL−1. The sensitivity to 
the inhibition of biofilm formation varied among the strains and depended on the compounds. ATCC 
19615 was more sensitive to 1,2-naphthoquinone but more resistant to 4-hexylresorcinol than the two 
other strains (Table 1) 
Table 1. Minimum inhibitory concentration (MIC, µg mL−1), minimum bactericidal concentration 
(MBC, µg mL−1) of 11 compounds and minimum biofilm inhibitory concentration (MBIC, µg mL−1) of 
the four most active compounds against three different strains of S. pyogenes. 
Streptococcus 
Pyogenes Strains Chemical Structure 
ATCC 19615 ATCC 49399 A Clinical Isolate 
Compounds MIC MBC MBIC MIC MBC MBIC MIC MBC MBIC
Phlorizin 
 
100 >100 a nd 100 >100 nd 100 >100 nd 
Naringenin 
 
50 >100 nd 50 >100 nd 50 >100 nd 
Flavone 
 
50 >100 nd >100 >100 nd 25 >100 nd 
Myricetin 
 
50 >100 nd 100 >100 nd 100 >100 nd 
Thymol 
 
25 >100 nd >100 >100 nd ≥100 >100 nd 
1,2-
Naphthoquinone 
 
3.125 100 25 6.25 100 50 6.25 100 50 
5-Hydroxy-1,4-
naphthoquinone 
 
1.56 100 12.5 1.56 >100 50 0.39 100 12.5 
Resveratrol 
 
100 >100 nd 50 >100 nd >100 >100 nd 
Cinnamaldehyde 
 
>100 >100 nd 50 >100 nd 25 >100 nd 
Dequalinium 
chloride 
 
0.39 12.5 0.78 0.78 25 0.78 0.78 12.5 0.39 
4-Hexylresorcinol 
 
1.56 50 25 6.25 50 12.5 12.5 50 12.5 
a MBC was higher than the maximum concentration of 100 µg mL−1 used in this study; nd: not-determined. 
SEM images showed the visual reduction of S. pyogenes ATCC 19615 biofilm in the presence of 
the MBIC of the four compounds by strongly reducing the concentration of the attached cells and 
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modifying their shape (Figure 2). The presence of 1% DMSO in BHI (Figure 2B) reduced the chain 
length of the cocci and biofilm density, and also appeared to shrink the cells slightly in comparison 
to BHI only treatment (Figure 2A). Figure 2C shows that 25 µg mL−1 of 1,2-naphthoquinone reduced 
strongly the concentration of the attached cells, leaving only a few long and thin chains comprised of 
shrunken, irregular cells. In the presence of 12.5 µg mL−1 of 5-hydroxy-1,4-naphthoquinone (Figure 
2D), smaller cells aggregated in clusters of chains. Figure 2E presents the effect of dequalinium 
chloride at 0.78 µg mL−1, which induced the formation of very small groups of bacterial cells and 
completely altered their shape. The MBIC of 4-hexylresorcinol (Figure 2F) affected the chain 
formation of the bacteria and only a few small chains containing 2–4 cells were observed.  
 
Figure 2. Scanning electron microscopy images of the effect of MBIC concentrations of the compounds 
on the biofilm formation by strain S. pyogenes ATCC 19615 at 37 °C: S. pyogenes in BHI (A) and with 
1% DMSO (B); S. pyogenes with 25 µg mL−1 of 1,2 naphthoquinone (C); 12.5 µg mL−1 of 5-hydroxy-1,4 
naphthoquinone (D); 0.78 µg mL−1 of dequalinium chloride (E) and 25 µg mL−1 of 4-hexylresorcinol 
(F). Magnification value: I, ×1000; II, ×5000; III, ×1000; IV, ×15,000; V, ×25,000. 
4. Discussion 
According to the literature, the MICs of phenolic compounds against pharyngitis pathogens 
range from 1.52 to 100 µg mL−1 [9–12]. Among all the phenolic compounds tested in this study, nine 
compounds showed an anti-Streptococcal activity at a concentration lower than 100 µg mL−1. Gyawali 
and Ibrahim. (2014) [8] stated that the hydroxyl (-OH) group in phenolic compounds may cause 
bacterial inhibition and described the importance of double bonds (number and position) in relation 
to antimicrobial effectiveness. Inferences could be made to the present study as, among the nine 
active compounds, the most anti-S. pyogenes naphthoquinones possess two carbonyl groups in an 
aromatic ring as part of their quinone structure. This hypothesis is supported by a recent review 
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which associated the oxydo-reduction activity of the quinone structure in 2-hydroxy-1,4-
naphthoquinone with the generation of reactive oxygen species (ROS) and damage of 
macromolecules such as DNA, proteins, and lipids [15]. Ndi et al. (2007) [11] isolated another 
naphthoquinone from Eremophila serrula, which also exhibited antagonism against S. pyogenes strain 
ATCC 10389 with low MIC (7.8 µg mL−1) and MBC (15.6 µg mL−1).  
Clinically, most antibacterials are described as potentially being both bactericidal and 
bacteriostatic. This was also observed in this study as the tested compounds. Even if a bactericidal 
action is preferred in the context of treatment, achieving a bacteriostatic effect may advantageously 
inhibit exotoxin production in Staphylococci and Streptococci thereby avoiding induction of the toxic 
shock syndrome [16]. In comparison with the kinetics of the tested compounds, rhodomyrtone—the 
potent bioactive compound from Rhodomyrtus tomentosa—appears to be slightly more effective: it 
exerted a faster bactericidal activity on S. pyogenes (within 5 and 6 h) at lower concentrations (6.5–12.5 
µg mL−1) [17]. However, rhodomyrtone (Sigma-Aldrich Co., Saint-Louis, MO, USA) is about 2000–
4500 times more expensive than the naphthoquinones tested.  
To the best of our knowledge, the anti-biofilm potential of naphthoquinones against S. pyogenes 
has not been explored. The inhibition of biofilm formation is an interesting way to prevent the 
formation of well-organized attached bacterial biofilms and, thus, pharyngitis. We observed that the 
naphthoquinones elicited significant anti-biofilm activity against S. pyogenes, with metabolic MBICs 
in the same range as 4-hexylresorcinol and this was confirmed by SEM, where S. pyogenes ATCC 
19,615 cells appeared less aggregated, showed morphological changes, and reduced biofilm 
formation. These observations are in accordance with the potential of phenolic compounds to damage 
the membrane structure as well as anti-S. pyogenes properties of phytochemicals such as anti-
adhesion, anti-biofilm, and quorum-sensing inhibition [2,8]. The generation of ROS during the bio-
reduction of naphthoquinones [15] might be linked to the loss of cell wall integrity observed. In 
addition, the visible effect of 1% DMSO on the bacteria, which do not appear on the growth (Figure 
1), could also slightly enhance the antibacterial effect of the phytochemicals. 
Considering the potential clinical application of our study, additional experiments could be 
conducted on combination of natural antibacterial agents and currently used antibiotics to enhance 
the present management practices against S. pyogenes. If the combination demonstrates a synergic 
and/or a complementary effect (e.g., anti-inflammatory and antitussive), it could become a combined 
treatment for patient’s pain relief. Moreover, it is also possible to incorporate the efficacious natural 
compounds in dehydrated honey lozenges. Honey itself has a recognized effect as being systemic 
antitussive and antimicrobial natural source [18–20]. Interestingly, a recent study reported that honey 
with a high phenolic content presented the highest antimicrobial activity [20]. Further investigations 
are required to affirm the synergic effect with honey but also understand the safety of the use of 
naphthoquinones in throat lozenges before making any recommendations for their use for managing 
streptococcal pharyngitis. 
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